Compare UNCY & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNCY | LNSR |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.9M | 142.0M |
| IPO Year | 2021 | N/A |
| Metric | UNCY | LNSR |
|---|---|---|
| Price | $6.06 | $10.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $44.50 | $15.00 |
| AVG Volume (30 Days) | ★ 451.4K | 75.5K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $59,141,000.00 |
| Revenue This Year | N/A | $30.80 |
| Revenue Next Year | $19,392.60 | $33.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.02 |
| 52 Week Low | $3.71 | $7.13 |
| 52 Week High | $11.00 | $17.31 |
| Indicator | UNCY | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 43.43 |
| Support Level | $5.96 | $9.56 |
| Resistance Level | $6.70 | $10.48 |
| Average True Range (ATR) | 0.46 | 0.37 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 63.68 | 74.71 |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.